A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-11. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
In its oxidized form, azurin (Cu2+Az) receives an electron from its redox partner and is reduced according to the following reaction: Cu2+Az + e− → Cu+Az The redox potential is 310 mV. The highly interconnected beta-sheet structure of azurin is strongly coupled with its electron-transfer center (the copper-binding side). Considerable experimental evidence exists to suggest that hydrogen bonds play a role in the long-distance electron transfer mechanism of azurin. Taken together, these observations suggest that electrons tunnel through the protein along its polypeptide and hydrogen bonds, making azurin a useful model system for studying long-range, intraprotein electron transfer (LRET).
Tranexamic acid is marketed in the US and Australia in tablet form as Lysteda and in Australia, Sweden and Jordan it is marketed in an IV form and tablet form as Cyklokapron, in the UK and Sweden as Cyclo-F. In the UK it is also marketed as Femstrual, in Asia as Transcam, in Bangladesh as Intrax & Tracid, in India as Pause, in Pakistan as Transamin, in Indonesia as Kalnex, in South America as Espercil, in Japan as Nicolda, in France, Poland, Belgium, and Romania as Exacyl and in Egypt as Kapron. In the Philippines, its capsule form is marketed as Hemostan and in Israel as Hexakapron. The US Food and Drug Administration (FDA) approved tranexamic acid oral tablets (brand name Lysteda) for the treatment of heavy menstrual bleeding in November 2009. In March 2011, the status of tranexamic acid for the treatment of heavy menstrual bleeding was changed in the UK, from POM (Prescription only Medicines) to P (Pharmacy Medicines) and became available over the counter in UK pharmacies under the brand names of Cyklo-F and Femstrual.
== External links == Ashton CH (2002). Benzodiazepines: how they work & how to withdraw (aka The Ashton Manual). Archived from the original on 17 July 2023. Retrieved 4 May 2024. Ashton CH (2007). "Benzodiazepine equivalence table". Fruchtengarten L (April 1998). Ruse M (ed.). "Benzodiazepines". Poisons Information Monograph (Group monograph) G008. International Programme on Chemical Safety INCHEM. Retrieved 9 June 2009. Longo LP, Johnson B (April 2000). "Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives". American Family Physician. 61 (7): 2121–2128. PMID 10779253. Archived from the original on 12 May 2008. Retrieved 25 May 2008.
Nedaplatin, sold in Japan as Aqupla (see External Links), is a platinum-based chemotherapy agent. It is toxic to DNA, causing damage to DNA, limiting DNA repair and ultimately limiting DNA synthesis, limiting the propagation of cancer cells.
14 April GNz7q, a distant starburst galaxy, is reported as being a "missing link" between supermassive black holes and the evolution of quasars. A study describes the impact of climate change on the survival of cacti. It finds that 60% of species will experience a reduction in favourable climate by 2050–2070, with epiphytes having the greatest exposure to increased warming. A preprint demonstrates how backdoors can be placed undetectably into classifying (e.g. posts as "spam" or well-visible "not spam") machine learning models which are often developed and/or trained by third parties. Parties can change the classification of any input, including in cases with types of data/software transparency, possibly including white-box access.
Sources: en.wikipedia.org
However, it is also possible to concentrate material from a dilute stream at the head of a chromatographic column and then switch conditions to elute the adsorbed material in conventional isocratic or gradient modes. Therefore, this approach is not unique to displacement chromatography, although the higher loading capacity and less dilution allow greater concentration in displacement mode. A disadvantage of displacement chromatography is that non-idealities always give rise to an overlap zone between each pair of components; this mixed zone must be collected separately for recycle or discard to preserve the purity of the separated materials. The strategy of adding spacer molecules to form zones between the components (sometimes termed "carrier displacement chromatography") has been investigated and can be useful when suitable, readily removable spacers are found. Another disadvantage is that the raw chromatogram, for instance a plot of absorbance or refractive index vs elution volume, can be difficult to interpret for contiguous zones, especially if the displacement train is not fully developed. Documentation and troubleshooting may require additional chemical analysis to establish the distribution of a given component. Another disadvantage is that the time required for regeneration limits throughput. According to John C.
=== The Taghi organisation === Ridouan Taghi is a former Dutch-Moroccan drug trafficker and crime boss. He was specialised in forming criminal groups and coalitions that operated as international cocaine cartels. He is suspected of being behind the orchestration of several assassinations, attacks, and kidnappings in connection to the Mocro-War. Documents produced by the Drug Enforcement Administration (DEA) of the United States, and sent to the Dutch police, exposed what appeared to be a super drug cartel headed by Ridouan Taghi, alongside Raffaele Imperiale (Camorra's drugs and arms dealer), Daniel Kinahan (Irish reputed gang boss) and Edin Gačanin (Bosnian drug trafficker). The DEA estimated that around a third of all cocaine trafficking in Europe was done through his organisation, with a virtually monopoly on Peruvian cocaine. After the decryption of the telecommunication servers of Ennetcom by the Dutch and Canadian authorities, it also exposed a very close and personal friendship between Ridouan Taghi, and Chilean cartel boss Rico "El Rico" Eduardo Riquelme Vega, who was arrested in Santiago, Chile in 2017. Following the arrest of Benaouf A. in 2013, and the assassinations of two rival drug lords, Gwenette Martha and Samir Bouyakhrichan in 2014, Taghi was able to establish himself as one of the most powerful drug traffickers in Europe. The Dutch government also considered him to be "one of the most dangerous drug traffickers in Europe". Ridouan Taghi was able to keep a very low profile and run his operation unknowingly for many years.
=== Artificial === De novo designed peptides which self-assemble in the presence of copper (Cu), forming supramolecular assemblies were presented by Korendovych et al. Additionally there are examples of metallopeptides that are, at least partially, composed of non-natural amino acids with possible applications in drug discovery and biomaterials.
In addition to expanding the tandem mass spectrometry database, METLIN is designed to search tandem mass spectrometry data, precursor mass, chemical formulas, compound names among other search capabilities. METLIN has also been implemented with cognitive computing applications. The tandem MS high-resolution ESI-QTOF MS/MS data on now over 960,000 distinct chemical entities, includes mass spectral collision-induced dissociation data at four different collision energies, in both positive and negative ionization modes.
Sources: en.wikipedia.org
Hookah, Sasuba and Snuba systems are categorised as "air-line" equipment, as they do not include the communication, lifeline and pneumofathometer hose characteristic of a full diver's umbilical. Most hookah diving uses a demand system based on a standard scuba second stage, but there have been special purpose free-flow full-face masks specifically intended for hookah diving (see photos). A bailout system, or emergency gas supply (EGS) is not an inherent part of an air-line diving system, though it may be required in some applications. Their field of application is very different from full surface-supplied diving. Hookah is generally used for shallow water work in low-hazard applications, such as archaeology, aquaculture, and aquarium maintenance work, but is also sometimes used for open water hunting and gathering of seafood, shallow water mining of gold and diamonds in rivers and streams, and bottom cleaning and other underwater maintenance of boats. Sasuba and Snuba are mainly a shallow water recreational application for low-hazard sites. Sasuba and hookah diving equipment is also used for boat maintenance and hull cleaning, swimming pool maintenance, and shallow underwater inspections. The systems used to supply air through the hose to a demand valve mouthpiece, are either 12-volt electrical air pumps, gasoline engine powered low-pressure compressors, or floating scuba cylinders with high pressure regulators. These hookah diving systems usually limit the hose length to allow less than 7 metres depth.
One measure of how well a molecule fits a receptor is its binding affinity, which is inversely related to the dissociation constant Kd. A good fit corresponds with high affinity and low Kd. The final biological response (e.g. second messenger cascade, muscle-contraction), is only achieved after a significant number of receptors are activated. Affinity is a measure of the tendency of a ligand to bind to its receptor. Efficacy is the measure of the bound ligand to activate its receptor.
== Career == Wang taught at the University of Chicago during and after her doctoral studies, and is considered the first Chinese woman to serve on the faculty of an American college. She was head of medical research at Michael Reese Hospital from 1920 to 1930. In the 1930s she worked at the children's hospital of the University of Cincinnati, on projects involving childhood metabolism, and in the 1940s she worked briefly for the Northwestern Yeast Company. She returned to academia from 1943 to 1946, as an assistant professor of physiology at Northwestern University Medical School. After a few years, she took a position with the Mayo Clinic. She was back at Northwestern University from 1950 to 1953, as associate professor biochemistry. From 1947 to 1954 Wang was associated with the metabolic laboratory at Hines Veterans Administration Hospital. At a Veterans Administration laboratory in Topeka after 1954, she was co-leader of studies on "Metabolism of Certain Types of Psychiatric Patients", "Effect on Blood Lipids of Orally Administered Detergents", and "A Study on the Influence of Foods on Serum Glutamic Oxalo-acetic Transaminase". She retired in 1961. Wang was chair of the Chinese students group at Wellesley, and one of the founding members of the Chicago Chinese Women's Club. She was elected to membership in the American Association for the Advancement of Science in 1922. In 1929 she was honored as a "woman leader" by a girls' organization in Chicago.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.